Preclinical · Biomarker · Genomic
The science between a target and a trial.
We design the preclinical programme, build the tissue and biomarker readouts that support it, and interpret the genomic data that comes back — so the result answers the question you actually need answered.
Focus areas
- Oncology
- Neurology
- Pulmonology
- Cardiology
- Gastroenterology
- Rare disease
- Microbial safety
01About
A practice, not a platform
The handoffs in translational research are where programmes lose time. The person who designs the study is rarely the person who reads the tissue, who is rarely the person who analyses the sequencing. Every seam is a delay.
One thread from question to report
The same scientist scopes the study, specifies the readouts, interprets what comes back, and writes it up — so there is no translation loss between the person who chose the endpoint and the person explaining what it showed.
Independent of any bench
We own no instruments, so there is no incentive to route your work toward equipment that needs keeping busy. Recommendations on vendors, assays and whether a dataset supports its stated conclusion are made without a commercial stake in the answer.
02Capabilities
Where we are useful
Six core service lines, each with a page of its own, plus immunophenotyping, scientific and regulatory writing, and sponsor-side CRO oversight.
Genomic & multi-omic analysis
Bulk and single-cell RNA-seq, WGS and WES, amplicon and microarray data taken from raw files through to pathway-level conclusions and publication-grade figures.
Read moreStrain ID & GRAS safety
Whole-genome taxonomic identification to strain level, genome characterisation, and systematic screening for resistance determinants, virulence factors and toxigenic potential.
Read morePreclinical programmes
Model selection, endpoint definition, power and sample-size rationale, protocol authorship, and independent review of what your vendors send back.
Read moreHistopathology & imaging
IHC and immunofluorescence assay development on FFPE and frozen sections, confocal imaging, whole-slide scanning, QuPath quantification and scoring strategy.
Read moreBiomarker & IVD strategy
Moving a discovery-stage signature toward an assay a clinical or diagnostic programme can actually use, with the regulatory pathway in view from the start.
Read moreOrganoid & ex vivo models
Organoids established from primary surgical and biopsy tissue under IRB approval, tumoroid systems, and ex vivo orthotopic models for patient-specific compound testing.
Read more03Data
Data in, report out
We are not tied to a platform or a vendor. Data arrives from your lab, your core facility, or your CRO — on whatever instrument produced it — and what comes back is a written report: interpreted, figured, and referenced.
- Sequencing data
- Bulk and single-cell RNA-seq, whole-genome and whole-exome, 16S and ITS amplicon, microarray — through QC, differential expression and pathway interpretation
- Imaging & histology
- Whole-slide images, IHC and immunofluorescence, confocal stacks. Scoring strategy, QuPath quantification, blinded read design
- Cytometry & assay
- FCS files from 12+ colour panels; compensation, gating, FlowJo. ELISA, multiplex cytokine, Luminex, MSD, qPCR
- What you receive
- A written report with annotated publication-grade figures, a methods section you can lift verbatim, a statistical appendix, and the analysis code so the result is reproducible without us
04Principal
Who does the work
Akash Gupta, Ph.D., M.L.S. Cert.
Founder & Principal Scientist
Fifteen years in preclinical and translational research across academic, CRO and pharmaceutical-funded settings — most recently as Scientist IV at the University of Arizona, leading biomarker discovery in pulmonary arterial hypertension and neonatal lung and gut disease.
Ph.D. in Biology, Illinois Institute of Technology. Graduate certificates in Clinical Research Management and Regulatory Science. Published as first or co-first author in Blood, Circulation and Translational Research.
Selected publications
- Tailored CD4+ lymphocytes expressing human CHAT protein as a novel vasodilator in PAH. Translational Research, 2025. First author.
- Deficiency of the deubiquitinase UCHL1 attenuates pulmonary arterial hypertension. Circulation, 2024. Co-first author.
- IL-18 mediates sickle cell cardiomyopathy and ventricular arrhythmias. Blood, 2021. First author.
Get started
Tell us what you are trying to find out.
If a preclinical question is stuck, a dataset is not saying what it was supposed to say, or a vendor deliverable does not look right — a twenty-minute call usually settles whether there is something here worth doing.